Skip to main content

Table 2 Incidences and hazard ratios of the composites of total CV events or non-CV deaths

From: Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Composite event

Dulaglutide group

Placebo group

Events avoideda

Conditional time gap model

Proportional means model

N (/1000py)

N (/1000py)

N (N/1000py)

HR (95% CI)

p

HR (95% CI)

P

MACE or non-CV death

932 (35.8)

1040 (40.3)

108 (4.5)

0.90 (0.82–0.98)

0.020

0.89 (0.80–0.98)

0.022

MACE, UA or non-CV death

1034 (39.7)

1123 (43.5)

89 (3.8)

0.92 (0.85–1.00)

0.052

0.91 (0.83–1.01)

0.066

MACE, HF or non-CV death

1195 (45.9)

1372 (53.2)

177 (7.3)

0.91 (0.84–0.99)

0.021

0.86 (0.78–0.96)

0.006

MACE, Revasc or non-CV death

1399 (53.8)

1519 (58.9)

120 (5.1)

0.92 (0.86–0.99)

0.030

0.91 (0.83–1.01)

0.0632

MACE, UA, HF, Revasc or non-CV death

1747 (67.1)

1926 (74.7)

179 (7.6)

0.93 (0.87–0.99)

0.023

0.90 (0.82–0.99)

0.028

  1. aDifference in numbers (and rate) of outcomes in the dulaglutide group versus the placebo group; N, number of outcomes; py, person-year; MACE, major adverse cardiovascular events; CV, cardiovascular; UA, unstable angina; HF, heart failure; Revasc, revascularization